NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
6.15
+0.01 (0.16%)
Oct 6, 2025, 4:00 PM EDT - Market closed
NanoVibronix Revenue
NanoVibronix had revenue of $494.00K in the quarter ending June 30, 2025, a decrease of -39.53%. This brings the company's revenue in the last twelve months to $2.34M, down -30.66% year-over-year. In the year 2024, NanoVibronix had annual revenue of $2.56M with 12.05% growth.
Revenue (ttm)
$2.34M
Revenue Growth
-30.66%
P/S Ratio
0.39
Revenue / Employee
$75,452
Employees
31
Market Cap
5.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.56M | 275.00K | 12.05% |
| Dec 31, 2023 | 2.28M | 1.53M | 203.59% |
| Dec 31, 2022 | 752.00K | -943.00K | -55.63% |
| Dec 31, 2021 | 1.70M | 1.07M | 172.07% |
| Dec 31, 2020 | 623.00K | 93.00K | 17.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NAOV News
- 18 days ago - NanoVibronix Launches “Oscar” Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities - Business Wire
- 20 days ago - NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Business Wire
- 21 days ago - NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical's Intellectual Property Portfolio - Business Wire
- 4 weeks ago - NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology - Business Wire
- 2 months ago - NanoVibronix Announces Reverse Stock Split - Business Wire
- 2 months ago - NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock - Business Wire
- 3 months ago - NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation - Business Wire
- 3 months ago - NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement - Business Wire